CL2021000301A1 - Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020. - Google Patents

Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020.

Info

Publication number
CL2021000301A1
CL2021000301A1 CL2021000301A CL2021000301A CL2021000301A1 CL 2021000301 A1 CL2021000301 A1 CL 2021000301A1 CL 2021000301 A CL2021000301 A CL 2021000301A CL 2021000301 A CL2021000301 A CL 2021000301A CL 2021000301 A1 CL2021000301 A1 CL 2021000301A1
Authority
CL
Chile
Prior art keywords
crystalline forms
sgc
stimulant
sun
guanylyl cyclase
Prior art date
Application number
CL2021000301A
Other languages
English (en)
Inventor
Thomas Storz
Leena Kumari Prasad
Kwame W Nti-Addae
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of CL2021000301A1 publication Critical patent/CL2021000301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación se relaciona con formas cristalinas de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1H-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina, que son útiles como estimuladores de guanilato ciclasa soluble (sGC). La presente divulgación también provee composiciones farmacéuticamente aceptables que comprenden las formas cristalinas y métodos para usar dichas composiciones en el tratamiento de diversas afecciones.
CL2021000301A 2018-03-07 2021-02-04 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020. CL2021000301A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862639846P 2018-03-07 2018-03-07

Publications (1)

Publication Number Publication Date
CL2021000301A1 true CL2021000301A1 (es) 2021-06-18

Family

ID=65818696

Family Applications (5)

Application Number Title Priority Date Filing Date
CL2020002284A CL2020002284A1 (es) 2018-03-07 2020-09-03 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc)
CL2021000301A CL2021000301A1 (es) 2018-03-07 2021-02-04 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020.
CL2021003530A CL2021003530A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020.
CL2021003531A CL2021003531A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020
CL2021003536A CL2021003536A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020002284A CL2020002284A1 (es) 2018-03-07 2020-09-03 Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc)

Family Applications After (3)

Application Number Title Priority Date Filing Date
CL2021003530A CL2021003530A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 1 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina solicitud divisional de solicitud 2284-2020.
CL2021003531A CL2021003531A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 2 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina. solicitud divisional de solicitud 2284-2020
CL2021003536A CL2021003536A1 (es) 2018-03-07 2021-12-28 Hidrato cristalino 3 de 8-(2-fluorobencil)-6-(3-(trifluorometil)-1h-1,2,4-triazol-5-il)imidazo[1,2-a]pirazina . solicitud divisional de solicitud 2284-2020

Country Status (20)

Country Link
US (2) US11466015B2 (es)
EP (1) EP3762389B1 (es)
JP (1) JP7423539B2 (es)
KR (1) KR20200128708A (es)
CN (1) CN111836812A (es)
AU (1) AU2019231724A1 (es)
BR (1) BR112020018212A2 (es)
CA (1) CA3092683A1 (es)
CL (5) CL2020002284A1 (es)
CO (1) CO2020012493A2 (es)
CR (1) CR20200458A (es)
EA (1) EA202092109A1 (es)
IL (1) IL276853A (es)
MA (1) MA54638A (es)
MX (5) MX2023004855A (es)
PE (1) PE20210124A1 (es)
PH (1) PH12020551394A1 (es)
SG (1) SG11202008641WA (es)
TW (1) TWI823903B (es)
WO (1) WO2019173551A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210177846A1 (en) * 2018-07-11 2021-06-17 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
US20230130739A1 (en) * 2020-03-26 2023-04-27 Cyclerion Therapeutics, Inc. DEUTERATED sGC STIMULATORS

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
HU228111B1 (en) 1998-07-08 2012-11-28 Sanofi Aventis Deutschland Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
BRPI0816382A2 (pt) 2007-09-06 2015-02-24 Merck Sharp & Dohme Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
JP2011510082A (ja) 2008-01-24 2011-03-31 メルク・シャープ・エンド・ドーム・コーポレイション アンジオテンシンｉｉ受容体拮抗薬
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
AU2010218224B2 (en) 2009-02-26 2013-06-27 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2011119518A1 (en) 2010-03-25 2011-09-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2575473B1 (en) 2010-05-27 2016-01-20 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2012058132A1 (en) 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CN104327107A (zh) * 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
EP3152214B1 (en) 2014-06-04 2020-01-29 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
EP3227286B1 (de) 2014-12-02 2018-12-26 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
CR20220309A (es) 2016-09-02 2022-09-16 Cyclerion Therapeutics Inc Estimuladores de sgc

Also Published As

Publication number Publication date
MX2023004858A (es) 2023-11-24
MX2023004856A (es) 2023-11-24
CL2021003530A1 (es) 2022-08-19
CA3092683A1 (en) 2019-09-12
CL2021003531A1 (es) 2022-08-19
JP7423539B2 (ja) 2024-01-29
IL276853A (en) 2020-10-29
MX2023004855A (es) 2023-11-24
CO2020012493A2 (es) 2020-10-30
US20210115050A1 (en) 2021-04-22
CL2021003536A1 (es) 2022-08-19
KR20200128708A (ko) 2020-11-16
EP3762389B1 (en) 2024-02-28
EP3762389A1 (en) 2021-01-13
SG11202008641WA (en) 2020-10-29
PH12020551394A1 (en) 2021-11-22
WO2019173551A1 (en) 2019-09-12
TW201940487A (zh) 2019-10-16
EA202092109A1 (ru) 2021-03-04
TWI823903B (zh) 2023-12-01
JP2021515015A (ja) 2021-06-17
PE20210124A1 (es) 2021-01-19
US11466015B2 (en) 2022-10-11
US20230095799A1 (en) 2023-03-30
MX2020009183A (es) 2020-10-08
MX2023004857A (es) 2023-11-24
BR112020018212A2 (pt) 2020-12-29
WO2019173551A8 (en) 2020-06-11
MA54638A (fr) 2021-11-10
CN111836812A (zh) 2020-10-27
CR20200458A (es) 2020-11-09
CL2020002284A1 (es) 2020-11-27
AU2019231724A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
CL2021000301A1 (es) Formas cristalinas de un estimulante de la guanilil ciclasa soluble (sgc). solicitud divisional de sol. 2284-2020.
PE20120121A1 (es) Derivados de imidazopirazina como inhibidores de syk
MX2019002313A (es) Estimuladores de guanilato ciclasa soluble (sgc) biciclicos fusionados.
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PE20211001A1 (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
UY25671A1 (es) Procedimiento para preparar imidazotrazinonas sustituidas por 2-fenilo
UY38349A (es) Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
PE20201185A1 (es) Inhibidores de la oxacina monoacilglicerol lipasa (magl)
NO20054208L (no) Nitrogen-substituerte heksahydropyrazino[1,2-a]pyrimidin-4,7-dionderivater, fremgangsmater for fremstilling og anvendelse derav som medikamenter
PE20171104A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
MX2010009414A (es) Derivados de imidazo-[1,2-b]-piridazina para el tratamiento de enfermedad mediada por cinasa de tirosina c-met.
PE20060274A1 (es) (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico
IS7319A (is) Fjölgervingar klópídógrelvetnissúlfats
MX2007004264A (es) Uso de inhibidores de cinasas jun n-terminales para el tratamiento de retinopat??a glaucomatosa y enfermedades oculares.
PH12021551196A1 (en) 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
MX2022010852A (es) Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclasa soluble (sgc).
WO2018089330A3 (en) Sgc stimulators
UY37262A (es) [8-(fenilsulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il](1h-1,2,3-triazol-4-il)metanonas
MX2021002794A (es) Metodo mejorado para la fabricacion de 3-[(1s)-1-imidazo[1,2-a]pir idin-6- iletil]-5-(1-metilpirazol-4-il)triazolo[4,5-b]pirazina y formas polimorficas de la misma.
PE20020581A1 (es) Derivados de pirazolpiridinas sustituidos con piridimidina como estimuladores de la guanilato ciclasa
MX2023008755A (es) Cristales de sal.
GB0229022D0 (en) Organic Compounds
CL2023002896A1 (es) 3,4-dihidro-2,7-naftiridin-1,6(2h,7h)-dionas como inhibidores de mek